SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Savara, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [2]. Group 1: Company Overview - Savara, Inc. is facing legal scrutiny following a class action complaint filed on September 8, 2025, concerning events that occurred between March 7, 2024, and May 23, 2025 [2]. - The complaint alleges that Savara's board failed to disclose critical information regarding the MOLBREEVI Biologics License Application (BLA), which lacked sufficient details on chemistry, manufacturing, and controls [8]. Group 2: Financial Impact - On May 27, 2025, Savara announced it received a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, leading to a significant stock price drop of $0.90 per share, or 31.69%, closing at $1.94 per share [8]. - The delay in regulatory approval for MOLBREEVI increased the likelihood that Savara would need to raise additional capital [8]. Group 3: Legal Actions - Investors who suffered losses during the class period are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and options [1][4]. - The law firm represents both individual and institutional investors in various litigation matters, indicating a broad scope of legal expertise [5].